Browse by ▼

Keryx Biopharmaceuticals

  • 3 Stellar Drugs Equal 3 Attractive Buying Opportunities

    By Mohsin Saeed - April 5, 2013 | Tickers: ACAD, KERX, SRPT

    A large number of drugs received FDA approval last year and it seems the number will only rise this year. Large biopharmaceuticals are still plagued by diminishing patent portfolios and are hunting for attractive takeover targets. The three companies discussed below have some amazing drugs that have already proven themselves in clinical trials. Investors should buy these stocks for their pipeline potential and consider them likely acquisition targets.

    Sarepta Therapeutics more »

  • 3 stellar drugs equal 3 attractive buying opportunities

    By Mohsin Saeed - April 3, 2013 | Tickers: ACAD, KERX, SRPT

    A large number of drugs received FDA approval last year and it seems the number will only rise this year. Large biopharmaceutical are still plagued by diminishing patent portfolios and are hunting for attractive takeover targets. The three companies discussed bellows have some amazing drugs which have already proven themselves in clinical trials. Investors should buy these stocks for their pipeline potential and consider them likely acquisition targets.

    Sarepta Therapeutics more »

  • Is Now The Time To Buy Keryx Pharmaceuticals?

    By Shazir Mucklai - February 25, 2013 | Tickers: KERX, PFE

    Recently, Keryx Pharmaceuticals (NASDAQ: KERX) achieved a new milestone as the company declared remarkable results from its Phase 3 trials of Zerenex. Zerenex is designed to control abnormally high levels of phosphate in the blood of End Stage Renal Disease (ESRD) patients. In the United States, there are about 500,000 patients that require this medication to survive. Worldwide, there are more than 2 million End Stage Renal Disease patients more »

  • Xerenex Kidney Treatment: A Game Changer for Keryx Biopharmaceuticals

    By Marivic Cabural - February 10, 2013 | Tickers: DVA, KERX, SNY

    Keryx Biopharmaceutical’s (NASDAQ: KERX) latest kidney drug called Zerenex is a game changer for the company after achieving positive results from its long-term Phase 3 study, which is the second and final obligation under the special protocol assessment (SPA) clinical program with U.S. Food and Drug Administration (FDA). Zerenex is a phosphate binder designed to treat hyperphosphatemia in patients suffering from end stage renal disease (ESRD).

    The company more »

  • Is There Any Upside Potential Left Here?

    By Jordo Bivona - February 8, 2013 | Tickers: KERX, SNY, SHPG

    Keryx (NASDAQ: KERX) announced successful top-line results from the long-term Phase 3 study of Zerenex (ferric citrate), its phosphate binder drug candidate based on ferric iron, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) who are on dialysis.  

    Results

    Zerenex met the primary endpoint of the study showing a change in serum phosphorus that was statistically significant when compared to a more »

  • A Look at Three Big-Time Biotech Movers

    By Brian Nichols - January 28, 2013 | Tickers: FURX, KERX, RPRX

    Monday produced some big-time biotech news that moved a number of high-profile stocks. In this article I am looking at what moved, why it moved, and what it may mean to investors.

    Keryx Biopharmaceuticals’ (NASDAQ: KERX) future is a little less uncertain

    It has been a volatile year for Keryx Biopharmaceuticals: The stock had fallen from $5.00 to $1.50 early in 2012 after top-line data for its drug more »

  • Will Kidney Disease Drug Success Push This Stock Higher?

    By Jordo Bivona - January 20, 2013 | Tickers: KERX, SNY, SHPG

    Keryx (NASDAQ: KERX) announced that its Japanese partner, Japan Tobacco, has filed its New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare for marketing approval of Zerenex in Japan. Zerenex is used to treat hyperphosphatemia in patients with chronic kidney disease (CKD).

    Efficacy and safety data from several successfully completed Phase 3 studies in CKD patients with hyperphosphatemia in Japan has provided ample support for the more »

  • Is Keryx Spring Loaded on Zerenex?

    By Jordo Bivona - December 24, 2012 | Tickers: KERX, SNY, SHPG

    Keryx (NASDAQ: KERX) announced disappointing news earlier this year for its cancer compound perifosine, but attention is now turning to the company's kidney disease treatment, Zerenex. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal more »

  • Long-Term BioTech Play

    By Mohamed Mounir - October 2, 2012 | Tickers: CPHD, KERX, NSPH

    Ahh, the excitement of Biotech Investing! Buy a company that is currently in clinical trials, wait for the data to be released, and then watch your investment go through the roof, right?

    Guess again!

    Biotech will break your heart more often than not

    I learned that the hard way with Keryx (NASDAQ: KERX) and Aeterna Zentaris (NASDAQ: AEZS). The two companies were set to release the results of Phase III more »

  • Keryx and Peers are Strong Buys

    By Jordo Bivona - May 28, 2012 | Tickers: ARNA, DNDN, IDIX, KERX, SPPI

    There is no shame in wanting to find cheap investments that pay off in the long run. The trouble is it can be tough to tell what is worth your money and what is cheap simply because it is worthless.

    Some are struggling companies that might never recover and I would encourage you to avoid the temptation of a low price. In other cases the prices are low, but the more »

  • Keryx: Still Better Than Big Pharma

    By Maxwell Fisher - April 12, 2012 | Tickers: KERX

    There is something to be said for pithy statements like, "Tough times don't last; tough people do." I believe this applies to strong biotech firms like Keryx Biopharmaceuticals (NASDAQ: KERX). If it has made it this far in the Great Recession, it should make it during our eventual recovery. In an additional David and Goliath vein, Keryx thrives in part due to its smaller, manageable size compared to its more »

  • What High-Risk Investors Can Learn From Keryx

    By Maxxwell A.R. Chatsko - April 4, 2012 | Tickers: AEZS, KERX

    I had originally submitted this article over the weekend explaining why Keryx Biopharmaceuticals (NASDAQ: KERX) was a good sell hovering around $5 a share. Although the company had not released results from its Phase III perifosine trial the shares had returned a phenomenal 92.27% in the first quarter. There were many reasons to believe the trial would be unsuccessful, as I pointed out here in early January. 

    I woke more »

  • Keryx: A Biotech For Aggressive Investors

    By Maxwell Fisher - March 30, 2012 | Tickers: DNDN, HGSI, JNJ, KERX

    Keryx Pharmaceuicals (NASDAQ: KERX) is a biotechnology company involved in the development of pharmaceutical products for treating life-threatening diseases. Currently, its main focus is on drugs that treat renal disease and cancer. It has two drugs in phase 3 trials: Zerenex (ferric citrate), which is an oral, iron-based compound used to treat patients with end-stage renal disease, and KRX-0401 (perifosine), an oral anti-cancer agent intended to treat advanced colorectal cancer more »

  • Keryx: A Great Pick For Aggressive Investors

    By Bobby Fisher - March 26, 2012 | Tickers: CRIS, KERX, MDVN, MYGN

    There’s something to be said for investing in companies that have admirable objectives. Keryx Pharmaceuticals (NASDAQ: KERX) is trying to help cure bowel cancer. It’s a worthy goal given that the recovery prospects for patients at this moment are bleak. But does that make Keryx stock a great investment?

    The company’s stock has soared in the last few weeks with news of impending data from their phase more »

  • Keryx Perifosine Analysis

    By Maxxwell A.R. Chatsko - January 11, 2012 | Tickers: AEZS, KERX, SPPI

    Keryx Biopharmaceuticals (NASDAQ: KERX) has attracted two types of investors: those who hate the company and those who love it. Their lead drug candidate, perifosine, is currently wrapping up Phase III trials for colorectal cancer with results expected very soon. The drug was licensed from AEterna Zentaris (NASDAQ: AEZS) several years ago. Unfortunately, there are several big reasons to believe the trial will not reach its primary endpoint.

    The "Feuerstein-Ratain more »